PairX Bio is at the forefront of developing next-generation cancer-selective biologics, focusing on identifying novel, tumor-selective cell surface variants that can serve as effective therapeutic targets. Their biology-driven, variant-specific approach aims to address the critical need for cancer-selective targets, which are often limited and can lead to dose-limiting toxicities due to their presence in healthy tissues. By leveraging intellectual property exclusively licensed from Duke-NUS Medical School, Singapore, PairX is advancing a robust pipeline of therapies designed to target prevalent cancers affecting substantial patient populations. This innovative strategy not only enhances the efficacy of treatments but also improves tolerability, making it a significant advancement in cancer therapy.

The company emphasizes the importance of selecting highly actionable drug targets that can be paired with optimal therapeutic modalities, such as T-cell engagers, antibody-drug conjugates, and bispecifics. By focusing on variants that have meaningful therapeutic windows and play a functional role in carcinogenesis, PairX Bio aims to unlock broad treatment opportunities for patients with difficult-to-treat cancers. Their approach is designed to benefit larger patient populations beyond those with specific oncogenic mutations, thereby addressing significant unmet medical needs in oncology and offering hope for improved outcomes in cancer treatment.

Singapore

PairX is pioneering the development of next-generation cancer-selective biologics by identifying novel, highly prevalent, tumor-selective cell surface variants. Our biology-driven approach reveals a new class of therapeutic targets that can be paired with a variety of optimal therapeutic modalities. Founded on IP exclusively licensed from Duke-NUS Medical School, Singapore, PairX is advancing a robust pipeline of potential first- and best-in-class tumor-selective therapies targeting prevalent cancers in substantial patient populations.

PairX Bio

Company Details